The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response

被引:412
作者
Haubrich, RH
Little, SJ
Currier, JS
Forthal, DN
Kemper, CA
Beall, GN
Johnson, D
Dubé, MP
Hwang, JY
McCutchan, JA
机构
[1] Univ Calif San Diego, Treatment Ctr, Data & Biostat Unit, San Diego, CA 92103 USA
[2] Univ Calif Irvine, Irvine, CA 92717 USA
[3] Univ So Calif, Los Angeles, CA USA
[4] Santa Clara Valley Med Ctr, Los Angeles, CA USA
[5] Harbor UCLA Med Ctr, Los Angeles, CA USA
关键词
adherence; antiretroviral therapies; therapeutic response; HIV RNA;
D O I
10.1097/00002030-199906180-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To correlate self-reported antiretroviral adherence with virologic suppression. Design: Prospective observational study of adherence to therapy nested in a randomized comparative trial of frequent versus infrequent monitoring of plasma HIV RNA. Setting: Five university-affiliated HIV clinics. Patients: A group of 173 HIV-infected patients with a mean baseline CD4 count of 142 x 10(6) cells/l (range 3-515) of whom 164 and 119 completed adherence questionnaires at 2 and 6 months, respectively. Intervention: Individualized, unrestricted antiretroviral therapy. Measurements: Patients were classified into four groups by adherence to therapy in the previous 4 weeks (< 80%, 80-95%, 95-99%, 100%). Plasma HIV RNA levels and CD4 lymphocyte counts were measured bimonthly. Results: Recreational drug or alcohol use was associated with decreased adherence, whereas frequency of HIV RNA monitoring, demographic variables, (age, gender, education, and risk group) and stage of disease had no effect. Greater HIV suppression at 6 months was seen across four categories of increasing adherence (P = 0.009 for linear trend). Patients reporting < 80% adherence at 6 months had a 0.2 log(10) copies/ml increase in HIV RNA and a loss of 19 x 10(6) CD4 cells/l compared with a 1.1 log(10) copies/ml decrease in HIV RNA and an increase of 72 x 10(6) CD4 cells/l in those reporting 100% adherence (P = 0.02). Conclusion: Self-reported poor adherence (< 80%) and drug or alcohol use predicted non-response of HIV RNA at 6 months of antiretroviral therapy. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:1099 / 1107
页数:9
相关论文
共 33 条
[21]  
MARKOWITZ M, 1996, ANTIVIRAL DRUG RESIS, P261
[22]   ZIDOVUDINE ADHERENCE AMONG INDIVIDUALS WITH HIV-INFECTION [J].
MUMA, RD ;
ROSS, MW ;
PARCEL, GS ;
POLLARD, RB .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 1995, 7 (04) :439-447
[23]  
PablosMendez A, 1997, AM J MED, V102, P164, DOI 10.1016/S0002-9343(96)00402-0
[24]   Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].
Palella, FJ ;
Delaney, KM ;
Moorman, AC ;
Loveless, MO ;
Fuhrer, J ;
Satten, GA ;
Aschman, DJ ;
Holmberg, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860
[25]  
REGGY A, 1998, 5 C RETR OPP INF CHI
[26]   COMPLIANCE WITH ZIDOVUDINE THERAPY IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS, TYPE-1 - A CROSS-SECTIONAL STUDY IN A MUNICIPAL HOSPITAL CLINIC [J].
SAMET, JH ;
LIBMAN, H ;
STEGER, KA ;
DHAWAN, RK ;
CHEN, J ;
SHEVITZ, AH ;
DEWEESDUNK, R ;
LEVENSON, S ;
KUFE, D ;
CRAVEN, DE .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 (05) :495-502
[27]   Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance [J].
Singh, N ;
Squier, C ;
Sivek, C ;
Wagener, M ;
Nguyen, MH ;
Yu, VL .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 1996, 8 (03) :261-269
[28]   Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: A meta-analysis of controlled trials [J].
Staszewski, S ;
Hill, AM ;
Bartlett, J ;
Eron, JJ ;
Katlama, C ;
Johnson, J ;
Sawyer, W ;
McDade, H .
AIDS, 1997, 11 (04) :477-483
[29]  
STEIGBIGEL RT, 1996, 3 C RETR OPP INF WAS
[30]   PROVIDER ASSESSMENTS OF COMPLIANCE WITH ZIDOVUDINE [J].
STEINER, JF .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (03) :335-336